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Abstract
Fibroblast growth factors (FGFs) and their receptors are highly conserved signaling molecules that have been
implicated in postnatal cardiac remodeling. However, it is not known whether cardiomyocyte-expressed FGF
receptors are necessary or sufficient for ventricular remodeling in the adult heart. To determine whether
cardiomyocytes were competent to respond to an activated FGF receptor, and to determine if this signal would result
in the development of hypertrophy, we engineered a doxycycline (DOX)-inducible, cardiomyocyte-specific,
constitutively active FGF receptor mouse model (αMHC-rtTA, TRE-caFgfr1-myc). Echocardiographic and
hemodynamic analysis indicated that acute expression of caFGFR1 rapidly and directly increased cardiac
contractility, while chronic expression resulted in significant hypertrophy with preservation of systolic function.
Subsequent histologic analysis showed increased cardiomyocyte cross-sectional area and regions of myocyte
disarray and fibrosis, classic features of hypertrophic cardiomyopathy (HCM). Analysis of downstream pathways
revealed a lack of clear activation of classical FGF-mediated signaling pathways, but did demonstrate a reduction in
Serca2 expression and troponin I phosphorylation. Isolated ventricular myocytes showed enhanced contractility and
reduced relaxation, an effect that was partially reversed by inhibition of actin-myosin interactions. We conclude that
adult cardiomyocytes are competent to transduce FGF signaling and that FGF signaling is sufficient to promote
increased cardiomyocyte contractility in vitro and in vivo through enhanced intrinsic actin-myosin interactions. Long-
term, FGFR overexpression results in HCM with a dynamic outflow tract obstruction, and may serve as a unique
model of HCM.
Citation: Cilvik SN, Wang JI, Lavine KJ, Uchida K, Castro A, et al. (2013) Fibroblast Growth Factor Receptor 1 Signaling in Adult Cardiomyocytes
Increases Contractility and Results in a Hypertrophic Cardiomyopathy. PLoS ONE 8(12): e82979. doi:10.1371/journal.pone.0082979
Editor: Vincenzo Lionetti, Scuola Superiore Sant'Anna, Italy
Received August 26, 2013; Accepted October 29, 2013; Published December 11, 2013
Copyright: © 2013 Cilvik et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health grant HL105732 (D. Ornitz), American Heart Association grant 0910110G (S. Cilvik),
and National Institutes of Health grant HL45742 (C. Nichols). Transgenic mouse production was made possible through the Washington University
Musculoskeletal Research Center (National Institutes of Health grant P30 AR057235). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: dornitz@wustl.edu
Introduction
Hypertrophy is an adaptive mechanism by which the heart
can respond to stress or injury. In response to postnatal
growth, pregnancy, or exercise, the heart undergoes
physiological hypertrophy, characterized by an increase in
myocyte length, absence of fibrosis, maintenance of chamber
dimension, and normal cardiac function. In response to injury
or stress, such as a myocardial infarction or increased
afterload, functional heart muscle compensates with
pathological hypertrophy, which initially maintains cardiac
function. Pathological hypertrophy is characterized by
increased myocyte width, fibrosis, decreased ventricular
chamber volume, and eventual cardiac dysfunction and failure
[1,2]. Additionally, hypertrophic cardiomyopathy (HCM), a
primary myocardial disorder, is most often caused by dominant
mutations in sarcomeric proteins and characterized by myocyte
hypertrophy and disarray, fibrosis, and maintenance of systolic
function [3,4]. Many studies have attempted to elucidate
mechanisms that result in hypertrophy, but this process
remains poorly understood, particularly with regard to
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mechanisms that distinguish advantageous physiological
hypertrophy from detrimental pathological hypertrophy.
Numerous studies have implicated the Fibroblast Growth
Factor (FGF) family in the development of postnatal cardiac
hypertrophy. Addition of FGF2 to cultured neonatal rat
cardiomyocytes repressed adult cardiac genes and induced
embryonic genes, an expression profile characteristic of
pressure overload-induced hypertrophy [5–9]. Furthermore, the
hypertrophy exhibited by paced adult rat cardiomyocytes was
prevented by an anti-FGF2 antibody [10]. Thus, it is not
surprising that mice lacking FGF2 develop significantly less
hypertrophy than wild-type mice after being subjected to
pressure overload by transverse aortic constriction (TAC) [11].
Many other studies have demonstrated that FGF2 is both
necessary and sufficient for the development of pathological
hypertrophy following injury. Systemic administration of FGF2
following acute myocardial infarction in rats induced significant
hypertrophy in non-infarcted myocardium [12]. Similarly,
another study demonstrated that Fgf2-/- hearts have decreased
cardiomyocyte hypertrophy and impaired cardiac function
compared to WT mice following MI, while FGF2-
overexpressing hearts showed enhanced cardiomyocyte
hypertrophy and preserved function [13]. Additionally, knockout
of Fgf2 prevented the development isoproterenol- and
angiotensin II-induced pathological hypertrophy in the adult
heart, while transgenic overexpression of FGF2 in the heart
showed an exacerbated hypertrophic response to β-adrenergic
stimulation, an effect mediated by signaling through ERK1/2
[14,15].
In addition to FGF2, FGF9 and FGF23 recently have been
implicated in postnatal cardiac growth. FGF23, a bone-derived
hormone that regulates serum phosphate levels, has been
found to cause pathological cardiac hypertrophy, an effect
mediated by calcineurin-NFAT signaling in isolated rat
cardiomyocytes [16]. Meanwhile, mice with inducible
cardiomyocyte-specific expression of FGF9 developed
physiological cardiac hypertrophy with normal diastolic and
systolic function and no changes in the expression of
pathological markers (Anp, Bnp, βMHC) [17]. Following MI,
these mice developed increased hypertrophy, greater capillary
density, decreased interstitial fibrosis, and attenuated induction
of pathological markers compared to control mice [17]. This
resultant physiological hypertrophy, however, was not the
result of direct FGF signaling in the cardiomyocyte, but rather
the result of endothelial cell-mediated paracrine signaling via
BMP6 [17].
Despite a relative abundance of studies investigating FGF
ligands in the development of cardiac hypertrophy, little is
known about the role of FGF receptors in this process. In this
study, we aimed to further understand the mechanisms
governing FGF signaling in the development of cardiac
hypertrophy, specifically with regard to how cardiomyocytes
respond to a direct FGF signal via FGF receptor 1 (FGFR1).
Given that overexpression of FGF2 alone is not sufficient to
induce hypertrophy and that FGF9-mediated physiological
hypertrophy is indirect, we hypothesized that adult
cardiomyocytes may not be competent to transduce an FGF
signal under baseline conditions, and that this repression would
be relieved following injury or stress to the heart.
To directly test this model, we engineered a transgenic
mouse line in which a ligand-independent constitutively-active
FGF receptor (caFGFR1-myc) could be cell-autonomously
induced specifically in cardiomyocytes through doxycycline
(DOX) administration to αMHC-rtTA, TRE-caFgfr1-myc double
transgenic mice (DTG, Figure 1A). We found that in vivo
induction of caFGFR1 in adult cardiomyocytes led to rapid
changes in cardiomyocyte contractile dynamics and a dynamic
mid-cavity obstruction in the left ventricle. This acute pathology
was followed by the progressive development of concentric
hypertrophy with increased cardiac mass and cardiomyocyte
size, interstitial fibrosis, and myocyte disarray characteristic of
HCM. Interestingly, systolic function was preserved, even after
six months of transgene induction. Examination of signaling
pathways suggested a mechanism in which activation of FGF
signaling in cardiomyocytes leads to the enhancement of
intrinsic actin-myosin interactions, a common mechanism
implicated in the pathogenesis of familial HCM. As such, this
model of caFGFR1 overexpression-induced HCM may be
useful for further investigation into the mechanisms involved in
HCM development and studies aimed at its reversal.
Materials and Methods
Generation of TRE-caFGFR1 transgenic mice.
TRE-caFGFR1 mice were generated by subcloning a cDNA
fragment encoding FGFR31C(R248C)-cmyc into pTRE2
(Invitrogen). The resultant pTRE2-FGFR31C(R248C) vector
was linearized and injected into fertilized FVB oocytes. Eight
founder lines were obtained and four were screened by
crossing the founder to αMHC-rtTA transgenic mice, feeding
double transgenic offspring doxycycline chow (Research
Diets), and assaying for transgene expression by western blot.
Western blotting was performed using antibodies against the c-
myc epitope and β-tubulin (see more detailed description of
Western blot below). All mice were maintained on a mixed
background, primarily C57/Bl6/129. Both male and female mice
were used in this study.
All procedures complied with the standards for the care and
use of laboratory animals as stated in the Guide or the Care
and Use of Laboratory Animals (NIH publication No. 85-23,
revised 1996), and all protocols were approved by the Animal
Studies Committee at Washington University School of
Medicine.
Echocardiography
Non-invasive ultrasound examination of the cardiovascular
system was performed using a Vevo 2100 Ultrasound System
(VisualSonics Inc, Toronto, Ontario, Canada) according to the
following procedures. First, mice were lightly anesthetized with
an intraperitoneal injection of 2% Avertin (tribromoethanol,
0.005 ml/g). One fifth of the initial dose was given as a
maintenance dose at regular intervals depending on the level
of anesthesia. Low-dose Avertin was used because it does not
have significant negative inotropic or chronotropic effects. Hair
was removed from the anterior chest with a combination of
FGFR1 Signaling in Cardiomyocytes
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Figure 1.  Inducible constitutively-active FGFR1 genetic system shows minimal baseline activity and rapid activation of
transgene expression.  (A) Schematic of a tetracycline response element (TRE)-Fgfr31c(R248C)-c-myc transgene. (B) Western
blot analysis demonstrates minimal baseline expression (DTG 0d), rapid induction (DTG 1d), and consistent expression of
caFGFR1 following feeding of DOX chow for various lengths of time (DTG 7d, 21d, 168d). ß-tubulin expression demonstrates equal
protein loading. (C-E) Uninduced DTG mice show no evidence of hypertrophy on gross measurement of biventricular weight/body
weight ratio (HW/BW, B; nDTG=7, ncontrol=7), histological measurement of mean cardiomyocyte cross sectional area (CM CSA, C;
nDTG=5, ncontrol=5), or echocardiographic measurement of diastolic left ventricular posterior wall thickness (LVPWd, D; nDTG=47,
ncontrol=23). (F) Minimal expression of caFGFR1 is sufficient to induce a small, but significant, increase in outflow velocity from the
proximal LV (nDTG=72, ncontrol=43). (G) QRT-PCR analysis (nDTG=4, ncontrol=4) shows no significant changes in markers of pathological
cardiac remodeling. (H) QRT-PCR analysis (DTG: n0d=4, n1d=7, n7d=5, n21d=6, n168d=4) shows a significant elevation in Fgfr1 mRNA
in uninduced DTG animals (0d) that dramatically increases within one day of transgene induction (1d). (I) No significant changes
were seen in downstream transcription factors Etv5 or Etv4 at baseline (0d), but significant induction was observed after one day of
DOX induction (1d). Fold change is versus corresponding time-matched controls (not shown; n0d=4, n1d=6, n7d=4, n21d=5, n168d=4).
Error bars = standard deviation. *p<0.05, ** p<0.01, + p<0.001.
doi: 10.1371/journal.pone.0082979.g001
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shaving and chemical hair remover, and the animals were
placed on a warming pad in a left lateral decubitus position.
Ultrasound coupling gel was applied to the chest. Examination
of cardiac structure and function under these near-physiologic
conditions was obtained with hand-held manipulation of the
ultrasound transducer. Care was taken to maintain adequate
contact while avoiding excessive pressure on the chest.
Complete two-dimensional, M-mode, and Doppler ultrasound
examination was performed from multiple views. After
completion of the imaging studies, mice were kept warm and
allowed to recover until returned to their cage. Digitally
acquired images were analyzed off-line on a computer
workstation running Vevo 2100 analysis software.
Hemodynamic Analysis
Adult mice were anesthetized with thiopental sodium (60
mg/kg IP). This anesthesia produces a near physiologic heart
rate of 500 beats/min, while still allowing for a surgical plane of
anesthesia. The mice were intubated and ventilated with a
Harvard ventilator set at 200-400 μl. The bilateral carotid
arteries were identified in the region of the trachea and the right
carotid was cannulated with a 1.4 French high fidelity
micromanometer pressure-volume catheter (SciSense
Advantage System, London, Ontario, Canada). The catheter
was advanced retrogradely through the aortic valve into the left
ventricle to assess pressure volume loops. Echocardiography
was utilized when appropriate to ensure proper localization of
the catheter and rule out catheter entrapment. Continuous
aortic pressures, LV systolic and diastolic pressures, the
derivative of LV pressure (dP/dT), and tau were recorded and
analyzed with SciSense analysis software. Pressure-volume
loops were analyzed before, during, and after an occlusion of
the transverse aorta to assess load-independent
measurements of myocardial contractility.
Exercise tolerance
To determine if chronic induction of caFGFR1 and the
resulting concentric hypertrophy would result in impaired
performance during forced exercise, adult mice were fed DOX
chow for six months and then subjected to an acute treadmill
stress test, where their exercise tolerance was measured by
the length of time they were able to run unassisted (time to
failure). Exercise tests were carried out using a state-of-the-art
Exer4-OxyMax motorized treadmill (Columbus Instruments,
Columbus, Ohio). Electrified bars delivered a very mild shock
when a mouse failed to keep pace with the belt. Mice began
running at 10 m/min, and the speed was increased by 3 m/min
every 3 minutes. Time to failure was reached when a mouse
remained on the electrified bar for a continuous 5 seconds.
Gross pathology and histological analysis
At study endpoints, mice were fully anesthetized with 2.5%
Avertin (0.015 ml/g IP), and total body weight was measured.
Hearts were removed, rinsed briefly in PBS, and then placed
into a solution of PBS saturated with potassium chloride to
arrest hearts in diastole. Both outflow tract and atria were
carefully dissected away, and biventricular weight was
measured. Normalized heart size was determined by
calculating the ratio of biventricular weight (mg) to overall
mouse weight (g; heart weight: body weight ratio). The apical
third of the heart was removed and flash frozen in liquid
nitrogen for protein or RNA analysis, while the remaining heart
tissue was fixed in 10% neutral buffered formalin for 24-48
hours at room temperature. Samples were then dehydrated in
70% ethanol, embedded in paraffin, cut in 5 µm sections, and
stained with H&E. Fibrosis was detected on sections using a
Picrosirius red stain kit (24901, Polysciences, Inc., Warrington,
PA) with Weigert’s iron hematolxylin counterstaining (HT1079,
Sigma-Aldrich, St. Louis, MO).
Fluorescein-tagged wheat germ agglutinin (FITC-WGA,
L4895, Sigma-Aldrich, St. Louis, MO) was used to label all cell
membranes, thus illuminating areas of increased interstitial
cells and also making quantitation of cardiomyocyte cross-
sectional area possible. Sections were dewaxed using xylenes,
rehydrated through an ethanol series to water, rinsed in PBS,
and then stained with FITC-WGA (1:100) for one hour at room
temperature. Finally, sections were rinsed and mounted in
Vectashield Hard Set with DAPI (H-1500, Vector Laboratories,
Burlingame, CA), and imaged using a Zeiss Apotome
Microscopy system. Five to ten images showing
cardiomyocytes in cross section were taken from different
regions of the ventricular wall in each sample, and mean
cardiomyocyte cross sectional area was determined by tracing
(using ImageJ software) the membrane of at least 300
cardiomyocytes per heart.
Protein extraction and Western blotting
Protein was extracted from flash frozen apical pieces of the
heart using RIPA buffer with freshly added 2% Protease
Inhibitor Cocktail (P8340, Sigma-Aldrich) and Phosphatase
Inhibitor Cocktail I and II (P2850 and P5726, Sigma-Aldrich).
Protein concentration was determined utilizing a Pierce BCA
assay kit (23225, Thermo Scientific, Rockford, IL). Total protein
(60 µg) was separated on NuPAGE Novex 4-12% Bis-Tris Midi
gels (WG1401, Invitrogen, Grand Island, NY) and transferred to
PVDF membranes (iBlot Gel Transfer Stacks PVDF Regular,
IB4010, Invitrogen). Membranes were blocked for one hour at
room temperature with gentle shaking in TBST (50mM Tris,
pH7.4, 150mM NaCl, 0.1% Tween20) containing 5% nonfat
milk, and then probed with the antibodies listed in Table S2 in
File S1 overnight at 4°C. After three rinses in TBST,
membranes were incubated for one hour at room temperature
in horseradish peroxidase-linked secondary antibodies, as
described in Table S2 in File S1, in TBST with 5% nonfat milk,
rinsed again in TBST, and developed using SuperSignal West
Femto Maximum Sensitivity Substrate (34096, Thermo
Scientific).
The membrane was then stripped utilizing multiple washes of
boiled 100 mM glycine and TBST wash buffer at room
temperature (glycine reprobing protocol using the iBlot dry
blotting system, Invitrogen) and sequentially reprobed with
additional antibodies. Protein bands were quantified by
densitometry, and protein loading was normalized to β-tubulin.
Phospho-ERK1/2 and phospho-Akt were normalized to total-
ERK1/2 and total-Akt protein levels, and then scaled relative to
controls, where control samples were set at a value of 1.
FGFR1 Signaling in Cardiomyocytes
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RNA isolation, cDNA synthesis, and quantitative RT-
PCR
RNA was extracted from flash frozen apical pieces of the
heart using a Qiagen RNeasy Mini kit (74104, Qiagen,
Valencia, CA), with on-column DNA digest. RNA concentration
was determined utilizing a Nanodrop spectrophotometer. cDNA
was made using the BioRad iScript Reverse Transcription
Supermix for RT-qPCR kit (170-8841, BioRad, Hercules, CA).
Quantitative RT-PCR was performed on an Applied Biosystems
(ABI) 7500 thermocycler using ABI Taqman® Fast Advaned
Master Mix (ABI #4444557) and Taqman® gene expression
assays listed in Table S3 in File S1 (ABI). All samples were
normalized to Hprt and then scaled relative to controls using
the standard ddCt method.
Inhibitor studies
Eight- to 12-week-old MHC-rtTA, TRE-caFGFR1 mice were
treated with one of the following drugs, starting one week prior
to addition of DOX chow and continuing throughout the one
week of transgene induction: Losartan (600mg/L in drinking
water, Sigma #61188), propranolol (500mg/L in drinking water,
Sigma #P0884), diltiazem (450mg/L in drinking water, Sigma
#D2521), Cyclosporine A (15mg/kg twice daily subcutaneous
injections, Sigma #30024), Wortmannin (1mg/kg/d IP, Sigma
#W1628), U0126 (1mg/kg IP every 3 days, Calbiochem
#662005), or PD173074 (1mg/kg/d IP, Pfizer), according to
published studies [18–23].
Myocyte Isolation, cell contractility, and sarcomere
length measurements
Ventricular myocytes from acutely-induced (24-48 hours
following doxycycline treatment) control or double transgenic
(caFGFR1-expressing) mice were isolated as previously
described [24]. Following isolation, the ventricular myocyte
suspension was washed 3 times in Wittenberg Isolation
medium containing (in mM): 116 NaCl, 5.4 KCl, 8 MgCl2, 1
NaH2PO4, 1.5KH2PO4, 4 NaHCO3, 12 glucose, 21 N-(2-
hydroxyethyl) piperazine-N’-(2-ethanesulfonic acid) (HEPES), 2
glutamine, supplemented with 1X essential vitamins (GIBCO),
1X essential amino acids (GIBCO), 50mg/ml BSA, 12.5mg/ml
Taurine, and with increasing concentrations of CaCl2 (150µM,
400µM, and 900µM). The cells were then washed with
Tyrode’s solution containing (in mM) NaCl, 137; KCl, 5.4;
NaH2PO4, 0.16; glucose, 10; CaCl2, 1.0; MgCl2, 0.5; HEPES,
5.0; NaHCO3, 3.0; pH 7.3–7.4. Freshly isolated myocytes were
transferred to a recording chamber mounted on the stage of a
Nikon Diaphot inverted microscope and superfused at 60ml/
hour with normal Tyrode’s solution. The cells were allowed to
settle for 5 minutes and were subsequently paced (5-10V) at
0.5 Hz for 5 minutes before recording. All experiments were
performed at room temperature. Video images of individual
myocyte contractions were acquired using a Myocam camera
(IonOptix), and a Fourier transform was applied to the dark/light
contrast of the A and I bands to calculate the sarcomere length.
Length traces were subsequently analyzed with the Ion Wizard
software (IonOptix). To assess the relaxation of diastolic
sarcomere length, cells were loaded with 100µM BAPTA-AM
(Sigma) for 1 hour prior to recording or were treated with
Tyrode’s solution containing 40mM 2, 3-butanedione
monoxime (BDM) (Sigma) during recording.
Statistical analysis
In all figures, error bars represent standard deviation, unless
otherwise noted. Statistical analysis was carried out using a
standard two-tailed student T-test, with a p<0.05 considered




constitutively-active FGF receptor 1 mouse model
To investigate the cell autonomous function of FGF signaling
in adult cardiomyocytes, we utilized the doxycycline (DOX)-
regulatable TET-on system with the αMHC-rtTA mouse line
[25]. We generated a tetracycline response element (TRE)-
Fgfr31c(R248C)-c-myc transgene, in which FGFR31c(R248C)
is a chimeric receptor consisting of the FGFR3c(R248C)
mutant extracellular and transmembrane domains fused to the
FGFR1 tyrosine kinase domain (Figure 1A). The
FGFR3c(R248C) mutation confers ligand-independent
constitutive activity [26]. By fusing this mutant FGFR3c
receptor to the FGFR1 tyrosine kinase domain, one can
produce a receptor that constitutively activates FGFR1
signaling in the absence of ligand. A c-myc tag was placed at
the C-terminal tail of FGFR1 to allow detection of mutant
receptor expression. For simplicity, the TRE-Fgfr31c(R248C)-c-
myc transgene will be referred to as TRE-caFgfr1.
αMHC-rtTA/TRE-caFgfr1 double transgenic (DTG) mice
were examined for expression of the c-myc tag and FGFR1 in
the absence of DOX to determine the basal level of transgene
activation and native FGFR1 expression in the adult mouse
heart. DTG mice without DOX displayed very low levels of c-
myc and FGFR1 expression (Figure 1B, DTG 0d), while single
transgenic TRE-caFGFR1 animals did not express the
transgene or native FGFR1 (Figure 1B, control 0d). To
determine if this level of basal transgene expression led to a
cardiac phenotype, we measured the ratio of biventricular heart
weight and total body weight (HW/BW ratio, Figure 1C), mean
cardiomyocyte cross-sectional area (Figure 1D), and in vivo left
ventricle (LV) diastolic posterior wall thickness (LVPWd, Figure
1E) and proximal LV peak outflow velocity (LV POV, Figure 1F)
in 12- to 14-week-old mice. Cardiac mass, myocyte size, and
LV wall thickness were comparable between DTG mice and
controls, while a small, but significant, increase was observed
in LV POV (1.01±0.61m/s vs. 0.57±0.18m/s, p<0.001).
We also utilized quantitative RT-PCR (qRT-PCR) to examine
the expression of markers of heart failure, hypertrophy, and
fibrosis (Figure 1G) [5,6,27,28]. While the expression of b-type
natriuretic peptide (Bnp) was slightly elevated, levels of atrial
natriuretic peptide (Anp), beta-myosin heavy chain (ßmhc), and
collagens 1 and 3 (Col1a1, Col3a1) were unchanged in
uninduced DTG hearts. In all studies, littermate controls
included single transgenic mice (αMHC-rtTA only, TRE-caFgfr1
only) or wild-type mice. No significant differences were
observed between the three control genotypes in any of the
FGFR1 Signaling in Cardiomyocytes
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analyzed parameters, and as a result, control data were
pooled.
To test whether αMHC-rtTA can confer inducible expression
of caFGFR1 in the heart, we examined c-myc and FGFR1
expression following the administration of DOX chow. One day
of DOX was sufficient to induce robust transgene expression,
which was maintained at consistent levels with chronic feeding
of DOX chow (Figure 1B). No transgene activation or native
FGFR1 expression was visible in controls. We also utilized
qRT-PCR to measure changes in Fgfr1 gene expression. While
Fgfr1 mRNA expression was significantly increased at baseline
(0d) in DTG mice (19.6±6.6-fold, p=0.001), expression
increased dramatically after one day on DOX (199±80-fold,
p<0.001) and was maintained at these levels with chronic DOX
feeding (Figure 1H). Additionally, we monitored gene
expression of the FGF-responsive ETS transcription factors
Etv4 and Etv5 (Figure 1I) [29,30]. Despite increased Fgfr1
expression, Etv4 and Etv5 gene expression remained
unchanged at baseline in DTG mice compared to controls.
Expression of both transcription factors increased significantly
after one day of transgene induction (Etv5:3.0±0.9-fold,
p<0.001; Etv4:2.6±1.1, p=0.004), and remained elevated with
chronic expression of caFGFR1.
In vivo characterization of phenotype development in
αMHC-rtTA, TRE-caFgfr1 mice
To determine the effect of activating FGF signaling in
cardiomyocytes, 12- to 14-week-old DTG animals and controls
were induced, and cardiac function was monitored over time
with echocardiography. LV diastolic posterior wall thickness
(LVPWd) was significantly elevated in DTG mice within one
day of DOX induction (0.99±0.20 vs. 0.88±0.02mm, p=0.001,
Figure 2A) and LV mass index was significantly elevated by
one week of induction (5.3±1.0 vs. 4.2±0.5mg/g, p=0.02, LVMI,
Figure 2B), and both parameters continued to increase
throughout six months of induction. LV internal diastolic
diameter (LVIDd) was significantly decreased within one week
of transgene induction (3.04±0.26 vs. 3.47±0.21mm, p=0.001,
Figure 2C) and remained relatively constant over time. Systolic
function, as measured by fractional shortening (FS) (Figure
2D), remained comparable between DTG animals and controls,
and was even significantly increased at three time points (1d,
42d, 126d). Video S1 provides representative short axis
echocardiography showing cardiac function and progression of
hypertrophy from baseline (0d DTG) through six months (168d
DTG) of induction, while Figure 2E displays representative
diastolic mid-ventricle short-axis still images from DTG animals.
Note the concentric and symmetrical increase in wall thickness,
the decreased chamber volume, and the apparent increase in
cardiac contractility.
To determine the effects of caFGFR1 on the relaxation and
contractile properties of the adult heart, we performed an in
vivo hemodynamic assessment after one day (Figure 3A, Table
S1 in File S1) and six weeks (Figure 3B) of transgene
induction. Following one day of induction, no significant
differences were observed in heart rate, dP/dtmax, dP/dtmin, end
systolic or diastolic pressure (ESP, EDP), or tau (Glantz)
values of relaxation (Table S1 in File S1). However, end
systolic volume (ESV) was greatly reduced (18.2±3.3 vs.
31.7±4.5mL, p=0.05), and end diastolic volume (EDV) was
significantly decreased in DTG mice compared to controls
(31.8±2.8 vs. 51.2±4.5mL, p=0.01). To assess load-
independent measures of contractility, the LV pressure-volume
(PV) relationship was assessed by briefly constricting the
transverse aorta and determining the end-systolic pressure-
volume relationship (ESPVR) between the baseline and
increased afterload PV loops. The slope of the ESPVR was
significantly elevated following 24 hours of caFGFR1 induction
(10.4±1.6 vs. 3.6±1.1, p=0.004, Figure 3A), suggestive of
increased contractility [31].
Six weeks of transgene induction resulted in an obstructive
phenotype, as indicated by the altered appearance of the LV
pressure recordings and dP/dt tracings seen in DTG animals
compared to controls (Figure 3B). Echocardiography was
utilized to ensure proper catheter placement and rule out
catheter entrapment in the ventricular wall as a cause of the
altered pressure tracings. The presence of marked dynamic
outflow obstruction and consequent alteration of PV loops
precluded reliable analysis of ESPVR after prolonged
transgene induction.
Echocardiographic Doppler analysis supported the findings
from the hemodynamic studies. Representative color Doppler
images from DTG mice induced for six weeks (Figure 3C,
bottom) showed a distinct point of flow convergence in the mid-
LV that was not seen in control mice (Figure 3C, top). Spectral
Doppler interrogation revealed markedly elevated late-peaking
outflow velocities at the point of the flow convergence (Figure
3D,E). As stated previously, DTG mice showed elevated
outflow velocities at baseline (Figure 1F); however, these
values were substantially lower than velocities seen after 24
hours of transgene induction (0d:1.01±0.61 vs. 1d:
2.98±0.80m/s, p<0.001) and did not affect phenotype
development. However, where possible, mice with peak outflow
velocities greater than 1.0 m/s at baseline were not utilized for
further analysis.
Histologic characterization of phenotype and
pathologic gene expression analysis
To further characterize the hypertrophy phenotype in DTG
mice, we performed gross and histological analysis of hearts
from DTG and control mice. Following 42 days of caFGFR1
induction, hearts were visibly larger in DTG animals (Figure
4A). This difference was more apparent after 300 days of
transgene expression, evident in Trichrome-stained cardiac
cross-sections (Figure 4B). After ten months of caFGFR1
expression, concentric hypertrophy was still present, without
any progression to LV dilatation. Patchy areas of myocyte
disarray (Figure 4C) and increased interstitial fibrosis (Figure
4D) were observed after 42 days of induction. Wheat germ
agglutinin staining showed large patches of densely packed
interstitial cells after six months of induction (Figure 4E) and
progressively increasing myocyte size with transgene induction
(Figure 4F). Cardiomyocyte cross-sectional area was
significantly increased by one week of caFGFR1 induction
(288±15 vs. 229±32µm2, p=0.002) and continued to increase
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Figure 2.  Induction of caFGFR1 in adult cardiomyocytes results in the development of concentric hypertrophy with
preservation of systolic function over time.  (A) LV diastolic posterior wall thickness (LVPWd, A) was significantly elevated by
one day of induction, while LV mass index (LVMI) was significantly elevated (B) and LV internal diastolic diameter (LVIDd) was
significantly decreased (C) within seven days of DOX induction. (D) Systolic function was maintained throughout 6 months of
transgene induction. Error bars = standard deviation. *p<0.05, **p<0.01, +p<0.001. 0d: nDTG=47, ncontrol=23; 1d: nDTG=8, ncontrol=4; 7d:
nDTG=17, ncontrol=7; 42d: nDTG=14, ncontrol=12; 84d: nDTG=4, ncontrol=4; 126d: nDTG=4, ncontrol=4; 168d: nDTG=4, ncontrol=4. (E) Representative
short axis echocardiographic images depicting the progression of hypertrophy in DTG animals from baseline to 168 days of
induction.
doi: 10.1371/journal.pone.0082979.g002
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Figure 3.  In vivo induction of caFGFR1 in adult cardiomyocytes leads to a hypercontractile phenotype with the
development of a dynamic obstruction in the proximal left ventricle.  (A) Representative pressure-volume (PV) loops at
baseline (1) and following increased afterload (2) in DTG mice and littermate controls induced with DOX chow for 24 hours. The
slope of the end systolic pressure-volume relationship (ESPVR, dotted line) is significantly elevated in DTG mice (n=3 for DTG and
control). (B) Representative pressure (top) and dP/dt (bottom) tracings suggesting the presence of a dynamic obstruction in DTG
mice induced for 42 days (nDTG=3, ncontrol=2). (C) Representative color Doppler images (blue = blood outflow, red = blood inflow) and
(D) spectral Doppler tracings illustrating flow convergence (yellow arrow) and a high velocity late-peaking jet originating from the
point of dynamic mid-cavity obstruction in DTG mice. (E) Quantitation of LV peak outflow velocity (LV POV) at the point of flow
convergence. Error bars = standard deviation. *p<0.05, **p<0.01, +p<0.001.
doi: 10.1371/journal.pone.0082979.g003
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through six months of induction (512±152 vs. 271±30µm2,
p=0.02, Figure 4G).
To confirm that the hypertrophy seen in DTG mice was
pathological, qRT-PCR was used to examine the expression of
markers of pathological ventricular remodeling (Figure 4H & I).
Anp and Bnp were significantly elevated in DTG mice after one
day of caFGFR1 induction (Anp:3.2±1.7-fold, p=0.01; Bnp:
7.7±4.2-fold, p=0.003), while ßMHC, Col1a1, and Col3a1 were
not significantly elevated until 42 days of transgene induction
(ßMHC:7.9±5.2-fold, p=0.02; Col1a1:1.5±0.4-fold, p=0.04;
Col3a1:4.4±2.3-fold, p=0.01).
Exercise tolerance
Double transgenic mice expressing caFGFR1 exhibited all of
the pathophysiological characteristics of hypertrophic
cardiomyopathy (HCM). Because one of the most common
clinical manifestations of HCM is exercise intolerance [3], it was
important to determine if chronic induction of caFGFR1 and the
resulting concentric hypertrophy would result in impaired
performance during forced exercise. Adult mice were fed DOX
chow for six months and then subjected to an acute treadmill
stress test, where their exercise tolerance was measured by
the length of time they were able to run unassisted (time to
failure). Interestingly, caFGFR1-expressing double transgenic
mice did not display any signs of exercise intolerance and were
capable of running for the same length of time as their
littermate controls (24.4 ± 1.0 vs. 21.5 ± 4.7 minutes, Figure S1
in File S1).
Reversibility of phenotype
One of the advantages of the Tet-on system is its potential
for reversibility—the removal of DOX inactivates the rtTA and
halts transcription of the transgene. To assess the reversibility
of the caFGFR1-induced phenotype, 12- to 14-week old DTG
mice and littermate controls were induced with DOX chow for
six weeks and then fed normal chow for six weeks. LV mass
index and LV internal diastolic diameter returned to near
control levels after DOX removal (Figure 5A,B). LV diastolic
posterior wall thickness (Figure 5C) was significantly reduced
by 16% after DOX removal, but remained significantly elevated
over controls. LV peak outflow velocity (Figure 5D), measured
at the point of flow convergence in the mid-ventricle, was the
most resistant to reversal, decreasing by 20% after DOX
removal, but remaining significantly elevated compared to
controls. Consistent with in vivo wall thickness, cardiomyocyte
cross-sectional area was reduced by 24% after DOX removal
but remained significantly larger than controls (Figure 5E).
To determine whether the continued presence of phenotype
was the result of resistance to reversibility or continued
expression of caFGFR1, Western blot analysis of c-myc
expression and qRT-PCR analysis for Fgfr1 gene expression
were performed. caFGFR1, as measured by the c-myc tag,
was still expressed at relatively high levels after 42 days of
DOX removal (DTG 42d ON,42d OFF), although expression
was significantly reduced compared to expression following
three weeks of DOX induction (DTG 21d; Figure 5F). This
continued expression of the c-myc tag following DOX removal
corresponded to a 54-fold increase of Fgfr1 compared to
controls (p<0.001), down 82% from the 299-fold seen following
transgene induction for 42 days (Figure 5G). Despite continued
transgene expression, expression of downstream mediators of
FGF signaling, Etv5 and Etv4 (Figure 5H), and markers of
pathological ventricular remodeling (Figure 5I) returned to
normal levels following 42 days off DOX.
Mechanisms mediating phenotype development
following induction of caFGFR1
FGF receptors can activate a variety of pathways, including
MAPK/ERK, PI3K/Akt, PLCγ, and STATs [32]. In an effort to
elucidate the mechanisms involved in the development of the
hypercontractility and hypertrophy seen in DTG mice, we
analyzed protein expression throughout the time course of
caFGFR1 induction. While there was a trend towards a
transient 2-fold increase in ERK1/2 activation after one day of
induction, this change was not consistent enough to achieve
significance (nDTG=8, ncontrol=5, Figure S2 in File S1), and no
changes were apparent beyond 24 hours of caFGFR1
induction. We also examined the activation of other MAPKs
(p38, JNK), as well as Akt, PLCγ, and STATs (Stat3, Stat5),
none of which showed any trends toward activation following
induction of FGF signaling in cardiomyocytes (Figure S2 in File
S1).
Because there was no clear activation of a pathway, or
pathways, directly downstream of the FGF receptor, we
examined other signaling pathways that could result in
hypertrophy or hypercontractility. We hypothesized that
induction of caFGFR1 could lead to increased sensitization of
cardiomyocytes to sympathetic signaling, since adrenergic
activation in the heart has been shown to both increase
contractility and cause hypertrophy in cardiomyocytes [33]. We
examined downstream targets of adrenergic receptors,
including protein kinase A (PKA), troponin I (TnI), and
phospholamban. No changes were observed in PKA activation
at any time during caFGFR1 induction. Phosphorylation of TnI
was significantly decreased by one week of transgene
expression (Figure 6), in contrast to what we would expect if
adrenergic signaling were increased. There was also a trend
towards decreased phosphorylation of phospholamban, but this
result was more variable than TnI phosphorylation (data not
shown). Alterations in calcium handling are also a common
mechanism in the development of hypertrophy [3,4]. Consistent
with a potential role for aberrant calcium signaling, we
observed significant downregulation of Serca2 after seven days
of transgene induction (Figure 6). In addition, ryanodine
receptor (RyR2) expression was significantly decreased at both
one day (57.6±4.8% of control, p<0.01) and seven days
(56.2±3.1% of control, p<0.01) following transgene induction;
whereas, there was no significant change in expression levels
of the sodium-calcium exchanger (NCX1) at these time points
(data not shown).
Cell autonomous effects of caFGFR1 expression on
cardiomyocyte physiology
Ten- to twelve-week-old DTG and control mice were induced
with doxycycline for 24-48 hours, and then unloaded cell
contraction was assessed in acutely isolated ventricular
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Figure 4.  Chronic induction of caFGFR1 results in a pathologic state with molecular and histologic characteristics of
hypertrophic cardiomyopathy.  (A) Induction of caFGFR1 for 42 days results in grossly enlarged hearts in DTG compared to
control mice. (B) Following 300 days of transgene induction, massive DTG hearts show concentric hypertrophy with no evidence of
progression to dilatation (scale bar = 1mm). (C,D) Histological examination of DTG hearts induced for 42 days reveals patchy areas
of myocyte disarray (H&E, 20x magnification, C) and fibrosis (picrosirius red, 20x magnification, D). Six months (168d) of transgene
induction results in patchy areas of increased interstitial cells illustrated by fluorescein-tagged wheat germ agglutinin staining (FITC-
WGA, 40x magnification, E). (F) FITC-WGA staining illustrating the progressive enlargement of cardiomyocytes in DTG mice (scale
bar = 20mm). (G) Quantitation of mean cardiomyocyte cross-sectional area (CM CSA). (H,I) QRT-PCR reveals significant
upregulation of pathological markers of LV remodeling. Fold change is versus corresponding time-matched controls (not shown).
DTG: n0d=4, n1d=7, n7d=5, n42d=4, n168d=4; controls: n0d=4, n1d=6, n7d=4, n42d=5, n168d=4. Error bars = standard deviation. *p<0.05,
**p<0.01.
doi: 10.1371/journal.pone.0082979.g004
FGFR1 Signaling in Cardiomyocytes
PLOS ONE | www.plosone.org 10 December 2013 | Volume 8 | Issue 12 | e82979
Figure 5.  Transgene induction for 42 days, followed by DOX removal for 42 days leads to partial phenotype reversal.  (A,B)
LV internal diastolic diameter (LVIDd, A) and LV mass index (LVMI, B) returned to near control levels after removal of DOX for 42
days (42 off). (C) LV diastolic posterior wall thickness (LVPWd) was significantly reduced in DTG mice (n=6) following DOX removal
(42 off), but remained significantly elevated compared to controls (n=4). (D) Despite decreasing significantly following removal of
DOX, peak outflow velocity (LV POV) from the proximal ventricle was still significantly elevated compared to controls. (E)
Cardiomyocyte cross-sectional area (CM CSA) was smaller than that seen following six weeks of caFGFR1 induction (42 on), but
cells were still significantly larger than controls following DOX removal (42 off). (F) Western blot analysis showing a significant
decrease but persistent expression of caFGFR1 following removal of DOX (DTG 42d ON 42d OFF), compared to transgene
expression after three weeks of induction (DTG 21d; protein samples from six weeks of induction were unavailable). (G-I) QRT-PCR
analysis demonstrating continued overexpression of Fgfr1 in DTG hearts following 42 days off DOX (gray bar), despite a large
reduction from the level of expression observed following 42 days on DOX (black bar, G). Expression of downstream mediators of
FGF signaling (H) and markers of pathological LV remodeling (I) are decreased to control levels 42 days following DOX removal.
Error bars = standard deviation. *p<0.05, **p<0.01, +p<0.001 compared to controls. #p<0.05 compared to DTG mice 42 days on
DOX.
doi: 10.1371/journal.pone.0082979.g005
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myocytes. Representative traces of sarcomere length during
myocyte contraction (Figure 7A) and quantitation of sarcomere
length demonstrate that DTG myocytes had significantly
shorter lengths at both diastole and systole (Figure 7B), with an
overall increase in fractional shortening (Figure 7C) compared
to myocytes from controls. These data suggest that caFGFR1
leads to both impaired relaxation and enhanced contraction in
cardiomyocytes.
To further examine the basis of incomplete relaxation, 2,3-
butanedione monoxime (BDM), which inhibits actin-myosin
interactions and slows cross bridge cycling [34,35], was applied
to isolated ventricular myocytes. BDM led to significant
lengthening of both control and DTG sarcomere lengths (Figure
7D). More importantly, myocytes from DTG mice experienced a
significantly greater increase in sarcomere length than controls
and approached a similar final relaxed sarcomere length to
controls following BDM addition (Figure 7E).
To determine whether the altered contractile properties in
DTG myocytes were the result of increased intracellular
calcium concentration (due to decreased calcium recycling),
Figure 6.  DTG mice have significantly decreased troponin I phosphorylation and Serca2 expression.  (A) Representative
Western blots depicting no changes in the expression of phosphorylated protein kinase A (P-PKA) and decreased expression of
phosphorylated troponin I (P-TnI) and Serca2. ß-tubulin was used as a loading control. Independent blots are separated by a thick
black line. (B) Densitometric quantitation of p-TnI/t-TnI and Serca2, demonstrating a significant decrease in both by seven days of
caFGFR1 induction. Fold change is versus corresponding time-matched controls (not shown). DTG (shown): n0d=5, n1d=8, n7d=8,
n21d=6, n168d=2; controls (not shown): n0d=2, n1d=5, n7d=4, n21d=3, n168d=2. Error bars = standard deviation. *p<0.05, **p<0.01.
doi: 10.1371/journal.pone.0082979.g006
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myocytes were loaded with BAPTA-AM, a membrane-
permeant calcium chelator [35]. In contrast to BDM, there was
no change in final relaxed sarcomere length in either control or
DTG myocytes, suggesting that enhanced contractility is
independent of cytosolic calcium levels (data not shown).
Clinical usefulness
Two classes of drugs that have been proven to reverse
pathological remodeling and improve cardiac function in heart
failure are angiotensin receptor antagonists, such as losartan,
and ß-adrenergic receptor antagonists, such as propranolol
[36]. While the precise mechanisms by which beta-blockers
Figure 7.  Ventricular myocytes from double transgenic mice have impaired relaxation and enhanced contraction.  (A)
Representative signal averaged sarcomere length measurements during contraction recorded from acutely-induced DTG (solid line)
and control cardiomyocytes (dashed line). (B) DTG myocytes had significantly shorter sarcomere lengths at both systole and
diastole, (C) with an overall increase in fractional shortening (n=4 mice, 17 myocytes total for both control and DTG). (D) Addition of
BDM caused significant relaxation of both DTG and control myocytes, and (E) resulted in a greater change in sarcomere length in
DTG myocytes (n=3 mice each, 19 control myocytes, 23 DTG myocytes). Error bars = standard deviation. **p<0.01, +p<0.001 DTG
vs. controls; # p<0.05 vs. respective baseline measurements.
doi: 10.1371/journal.pone.0082979.g007
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improve cardiac function and promote reverse remodeling are
unknown, this treatment is one of the mainstays for the
symptomatic relief of obstructive HCM due to its ability to
decrease the outflow gradient [36,37]. Meanwhile, losartan is
contraindicated in patients with LV outflow obstruction due to
its effect on blood pressure (which can increase the outflow
gradient) [38], but recent studies have indicated that blockade
of angiotensin signaling can prevent much of the pathological
remodeling in animal models of HCM [23].
To examine the clinical usefulness of this new model of
HCM, DTG mice were given losartan (80 mg/kg/d) or
propranolol (67 mg/kg/d) in their drinking water to determine if
these drugs could prevent or lessen phenotype development
(Figures S3, S4 in File S1). Treatment began one week prior to
the start of DOX chow, and continued throughout one week of
transgene induction. Both drugs abrogated the hypertrophic
response seen in untreated DTG mice induced for one week,
as assessed by in vivo LV mass index (Figures S3A, S4A in
File S1). The increase in LV posterior wall thickness was also
moderately blocked with both drugs, although neither treatment
caused a significant reduction (Figures S3D, S4D in File S1).
Only propranolol significantly reduced the dynamic obstruction,
as measured by LV outflow velocity (Figures S3B, S4B in File
S1), although it was still significantly elevated compared to
measurements taken prior to drug treatment and caFGFR1
induction (DTG+Pro, 0d) (Figure S3B in File S1). These studies
suggest that this model of caFGFR1-induced HCM may prove
useful to evaluate other treatments aimed at preventing or
reversing the course of this pathological condition.
Discussion
Induction of caFGFR1 in adult cardiomyocytes results
in hypercontractility and a hypertrophic
cardiomyopathy
In this study, we created a new mouse model in which we
could induce FGF receptor signaling specifically in
cardiomyocytes in an attempt to better understand the
relationship between cardiomyocyte FGF signaling and the
development of hypertrophy. We hypothesized that adult
cardiomyocytes are not competent to respond to an FGF signal
due to repression of the FGF signaling pathway under
homeostatic conditions. However, we discovered that cell
autonomous activation of FGF signaling was sufficient to
induce significant concentric hypertrophy within seven days of
transgene expression that progressively increased throughout
ten months of caFGFR1 expression. Patchy areas of fibrosis,
elevated expression of pathological cardiac markers, myocyte
disarray, and maintenance or enhancement of systolic function
support the notion that sustained activation of FGF signaling in
adult cardiomyocytes leads to a hypertrophic cardiomyopathy.
In addition to the development of HCM, caFGFR1 rapidly
increases the contractility of the heart within 24 hours of
induction. This hypercontractility resulted in narrowing of the
ventricular cavity during systole, leading to a high velocity jet of
blood flowing past the papillary muscles in the mid-ventricle.
This effect was further amplified to the point of a dynamic
obstruction following the development of concentric
hypertrophy, as evidenced by the significant elevation in end
systolic pressure in the distal ventricle. The hypercontractility
phenotype is extremely sensitive to activation of FGF signaling,
as it was significantly elevated even at baseline due to a small
amount of caFGFR1 expression in DTG mice, and it was
resistant to reversal following removal of DOX. Hypertrophic
parameters approached near control levels after six weeks off
DOX, while peak outflow velocity remained significantly
elevated. The fact that DTG mice at baseline do not show signs
of hypertrophy, despite having increased contractility, suggests
that a low level of activated FGFR1 in cardiomyocytes directly
regulates cardiac contractility, while prolonged exposure to
high levels of activated FGFR1 leads to the development of
HCM.
Constitutively-active FGFR1 in cardiomyocytes alters
mechanisms common to HCM pathophysiology
HCM affects one out of 500 adults and is the most common
cardiovascular genetic disorder. The majority of cases
(45-70%) can be attributed to dominant mutations in
sarcomeric proteins (over 800 mutations in 11 different
contractile genes) [3]. Many HCM patients, however, lack one
of these known mutations. In addition, this is a complex and
heterogeneous disease, and the correlations between
genotype and phenotype remain poorly understood. To our
knowledge, no study has shown that overactivation of FGFR1
is linked to HCM. However, mutations that lead to increased
Ras activity, a known mediator of the FGF signaling cascade,
are associated with the development of HCM (as well as a host
of other cardiac and syndromic defects) [39]. To determine the
mechanisms that lead to hypercontractility and the
development of HCM in this model, we examined pathways
known to be activated by FGFRs (ERK1/2, p38, JNK, Akt,
PLCγ1, Stat3, Stat5), but changes tended to be transient and
inconsistent, and thus inconclusive. However, expression of the
downstream FGF-responsive target genes, Etv4 and Etv5,
were consistently and persistently increased. Given the lack of
clear activation of one particular pathway, or pathways, it does
not appear that these classical downstream signaling pathways
are directly involved in the development of hypercontractility or
progression of hypertrophy observed in this model. Similar to
our findings, there was no increase in phosphorylated ERK or
Akt in a Ras-induced HCM mouse model [40], suggesting that
a novel or nonclassical pathway was responsible for
development of the HCM phenotype.
We then turned our attention to other possible mechanisms
for the development of hypercontractility and HCM, and
hypothesized that expression of caFGFR1 resulted in
cardiomyocytes that were hypersensitive to sympathetic
stimulation. ß-adrenergic receptor activation in cardiomyocytes
leads to synthesis of cAMP and activation of protein kinase A
(PKA), which phosphorylates downstream targets, such as
myofilament proteins (troponin I, myosin binding protein C), ion
channels, and calcium handling proteins (phospholamban).
Phosphorylation of these targets leads to increased inotropy
and lusitropy in cardiomyocytes [33]. However, caFGFR1-
expressing hearts showed no increase in PKA activation, and
significantly decreased phosphorylation of troponin I (TnI) by
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one week of DOX induction, suggesting that sympathetic
hypersensitization was not the mechanism for the increased
contractility.
Decreased TnI phosphorylation has important implications
for the mechanism of phenotype development in this model.
TnI is a sarcomeric protein that regulates contraction and
relaxation. TnI inhibits the interaction between actin and
myosin during diastole, when cytosolic calcium concentration is
low. During systole, the calcium concentration rises, calcium
binds to troponin C (TnC) and leads to a conformational
change in the troponin complex that removes TnI inhibition of
cross bridge formation and promotes sarcomere contraction.
Phosphorylation of TnI by protein kinase A or C represents an
important regulatory mechanism to modulate the contractile
properties of the myofilament, as it increases the amount of
calcium necessary for activation of contraction (i.e., it
decreases the calcium sensitivity of the sarcomere) and
increases the rate of calcium dissociation [41,42]. This results
in accelerated relaxation and increased crossbridge cycling.
Therefore, the decrease in TnI phosphorylation seen in this
model would result in increased calcium sensitivity of the
sarcomere, leading to contraction at lower calcium
concentrations, and ultimately to impaired relaxation. Further
evidence that caFGFR1 affects myofilament physiology came
from studies of ventricular myocytes isolated from DTG and
control hearts. Baseline recordings revealed that DTG
myocytes were significantly shorter during diastole than control
myocytes, suggesting the presence of a relaxation defect. DTG
myocytes also had significantly increased contractility
(fractional shortening), suggesting that caFGFR1 leads to
intrinsic changes in cardiomyocyte contractile properties. We
then subjected these myocytes from DOX-induced DTG and
control mice to 2,3-Butanedione monoxime (BDM), an inhibitor
of actin-myosin interactions, which significantly increased
diastolic sarcomere length in both control and DTG myocytes.
While DTG myocytes experienced a greater overall change in
sarcomere length, they remained significantly shorter than
control myocytes, indicating a partial reversal of the relaxation
defect. These data strongly suggest that alterations in
cardiomyocyte contractility (specifically relaxation) that result
from expression of caFGFR1 are due to intrinsic changes in
myofilament physiology. While it is likely that decreased TnI
phosphorylation plays a role in the pathophysiology of this
model, we did not observe significant changes in p-TnI until
seven days of transgene induction, suggesting that other
modifications to the contractile apparatus may occur earlier.
Further studies will be necessary to determine precisely how
acute activation of FGF signaling affects myofilament
physiology. Mechanisms involved in TnI dephosphorylation are
much less clear than those governing phosphorylation,
although it has been demonstrated that protein phosphatases 1
or 2A (PP1, PP2A) are capable of dephosphorylating TnI
[41,43–46]. Importantly, activation of PP2A has been
implicated as a feedback mechanism downstream of FGFR
activation [47–49], making this one possible mechanism by
which caFGFR1 could have direct effects on myofilament
physiology. The potential involvement of protein phosphatases
in the pathology of HCM was further implicated in a study
utilizing a transgenic mouse model of activated Ras [40].
Regardless of the specific mechanism, decreased TnI
phosphorylation and the resulting increased myofilament
calcium sensitivity provides a common link between this
caFGFR1-mediated HCM and classical models involving
sarcomere mutations. At least 62 mutations have been
identified in thin filament regulatory proteins (tropomyosin,
troponin T, and troponin I), many of which have been shown to
increase myofilament calcium binding affinity and one of which
prevents PKA-mediated phosphorylation [50,51].
Another proposed model for the development and
progression of HCM is abnormal intracellular calcium handling
[3,4]. Mouse models of HCM have demonstrated decreasing
levels of calcium handling proteins, as well as diminished
calcium transients and release of calcium from the SR [20,40].
One study even demonstrated that administration of diltiazem
before the emergence of hypertrophy was sufficient to maintain
normal levels of calcium handling proteins and prevent
phenotype development [20]. As a result, we examined the
expression levels of various calcium handling proteins, and
found that both Serca2 and ryanodine receptor (RyR2)
expression were significantly reduced following induction of
caFGFR1. Downregulation of Serca2 could potentially result in
decreased SR calcium concentration and higher cytosolic
calcium concentration. However, published data demonstrate
that a reduction in Serca2 expression reduces cardiac
contractility and accelerates the progression to heart failure
[52], in contrast to the hypercontractile phenotype and lack of
systolic dysfunction seen in caFGFR1-induced HCM. Thus, it is
more likely that Serca2 is downregulated to compensate for the
increased contractility in caFGFR1-expressing hearts.
Similarly, decreased RyR2 expression might be expected to
decrease calcium-induced calcium release from the SR and
thus reduce contractility [53], which suggests that the observed
decreased RyR2 expression may be a compensatory change
due to the hypercontractility phenotype resulting from
caFGFR1 induction. Furthermore, BAPTA-AM, a membrane-
permeable calcium chelator, had little effect on sarcomere
length in control or DTG myocytes, strongly suggesting that an
elevated cytosolic calcium concentration is not responsible for
the changes in cardiomyocyte physiology.
Clinical applications
To assess the clinical usefulness of this model, we treated
DTG mice with drugs shown to be effective in the management
of HCM. ß-adrenergic receptor antagonists, such as
propranolol, are used for the symptomatic relief of obstructive
HCM to decrease the outflow gradient, although the precise
mechanisms by which they improve cardiac function and
promote reverse remodeling are unknown [36,37]. Additionally,
angiotensin receptor antagonists, such as losartan, have been
shown to prevent much of the pathological remodeling in
animal models of HCM [23], although this drug is
contraindicated in patients with LV outflow obstruction due to
its effects on blood pressure [38]. Consistent with these data
from clinical and animal studies, propranolol significantly
reduced both the hypertrophy and dynamic obstruction in DTG
mice, while losartan moderately prevented the hypertrophic
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response, without affecting the obstructive phenotype. These
studies demonstrate that this model will be very useful for the
evaluation of treatments aimed at preventing, or even
reversing, the pathophysiology of HCM.
Conclusions and Future Directions
The studies presented here have only begun to address
mechanisms of adult cardiac FGF signaling, as many
significant questions remain. These studies make no
assumptions regarding FGF ligands that may be involved in the
regulation of cardiomyocyte contractility and hypertrophy, nor
do we propose that activation of FGF receptors 2-4 will result in
the same phenotype. Additionally, regulation of FGF signaling
and activation of intracellular signaling cascades is poorly
understood and beyond the scope of this paper. While multiple
studies have demonstrated FGF2’s involvement in the
development of pathological hypertrophy following injury,
limited research has examined the expression or role of other
FGF ligands or FGF receptors in the adult heart.
These studies address consequences of FGF signaling on
cardiovascular physiology and remodeling. While many
classical mouse models of human HCM exist, our doxycycline-
inducible cardiomyocyte-specific caFGFR1 mouse is unique in
that it is inducible, reversible, and mediated by a non-
sarcomeric protein. This model can be utilized to examine the
common pathways that lead to phenotype development, as
well as the extent of phenotype prevention and/or reversibility.
This model also suggests the possibility that activating
mutations in FGFR1 may directly lead to HCM or may modify
the phenotype when combined with mutations in other proteins.
Finally, perhaps the most striking finding from these studies is
that low levels of activated FGFR1 have rapid and potent
effects on cardiac contractility without any pathological effects,
suggesting that targeted activation of the FGF signaling
pathway may be beneficial to patients with heart failure and
poor systolic function. Further investigation is necessary to
more precisely elucidate the mechanisms responsible for the
increased contractility following expression of caFGFR1, as
well as pathways involved in the rapid progression from
hypercontractility to HCM.
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